Pediatric Brain Tumor Market Striking Growth US $ 1659.4 Million at CAGR ~4.1% Forecasts To 2023

16 October, 2017

The Global Pediatric Brain Tumor Market is growing at the CAGR of ~4.1% during the forecast period and expected to reach US$ 1659.4 million by 2023. Market Research Future published a research report on “Pediatric Brain Tumor Market” - Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.

Pediatric brain tumor is uncontrolled or abnormal growth of normal cell in the brain in children. Brain tumors mainly are of two types, cancerous (malignant) and noncancerous (benign). It is second most common type of cancer in children and it comprise about 25% of childhood cancer.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/3690 .

Major Key Players Analysis:

Abbott. (US),

AbbVie Inc. (US),

Akorn, Inc. (US),

Agios, Inc. (US),

Baxter (US),

Bayer AG (US),

Epizyme, Inc. (US),

Novartis AG (Switzerland),

Mylan N.V. (US) and others.

The cases of pediatric tumors are increasing globally that leading the growth of the market. Advanced diagnostic technology and new treatments are also major driving forces of the market. Rising healthcare infrastructure extended insurance cover, government initiatives, and emerging economies are driving the market. Rising funding for R&D and clinical trials as well as FDA approvals are also major growth factors for global pediatric brain tumor market.

Segmentation:

Global pediatric brain tumor market has been segmented on the basis of types which comprises of gliomas, mixed neuronal-glial tumors, embryonal tumors, choroid plexus papilloma/carcinoma, non-neuroepithelial tissue tumors, meningeal tumors, and others. Gliomas is further sub-segmented into astrocytoma, malignant gliomas, and others. Mixed neuronal-glial tumors are further sub-segmented into ganglioglioma, subependymal giant cell tumor, pleomorphic xanthoastrocytoma, and others. Embryonal tumors are further sub-segmented into primitive neuroectodermal tumor (PNET), atypical teratoid/rhabdoid tumor, and others. Tumors arising from non-neuroepithelial tissue are further sub-segmented into craniopharyngioma, pineal region tumors, and others.

On the basis of diagnosis, it is segmented into physical exam, Imaging tests, brain or spinal cord tumor biopsy, Llmbar puncture (spinal tap), blood and urine tests, and others. Imaging tests are further sub-segmented into Magnetic Resonance Imaging (MRI) scan, Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Angiogram, and others. Magnetic Resonance Imaging (MRI) scan is further sub-segmented into Magnetic Resonance Angiography (MRA), Magnetic Resonance Spectroscopy (MRS), Magnetic resonance perfusion, Functional MRI (fMRI), and others. Brain or spinal cord tumor biopsy is further sub-segmented into Stereotactic needle biopsy, Craniotomy, and other.

On the basis of treatment, the market has been segmented into surgery, therapies, drug treatment, and others. Surgery is further sub-segmented into surgical biopsy, resection (removal), Shunt placement/revision, and others. Therapies includes Radiation therapy, Chemotherapy, Targeted therapy, and others. Chemotherapy includes Carboplatin, Carmustine (BCNU), Cisplatin, Cyclophosphamide, Etoposide, Lomustine (CCNU), Methotrexate, Temozolomide, Thiotepa, Vincristine, and others. Drug treatment is further sub-segmented into Corticosteroids, Anti-seizure drugs (anti-epileptics), Hormones, and others.

Get Discount @ https://www.marketresearchfuture.com/check-discount/3690 .

Major TOC of Pediatric Brain Tumor Market:

Research Methodology

Market Dynamics

Global Pediatric Brain Tumor Market, Applications

Global Pediatric Brain Tumor Market, By Types

Global Pediatric Brain Tumor Market, By Competitive Landscape

Global Pediatric Brain Tumor Market, By Region

Competitive Landscape

Company Profiles

….Continued

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Start Publishing

Saurabh Sinha


More related article